Schering gets European OK for Zevalin for NHL

German pharmaceutical company Schering has received European Commission marketing approval for its radioimmunotherapy product Zevalin (ibritumomab tiuxetan), according to the Berlin-based firm.

Schering received the EU approval for the product to treat adult patients with rituximab relapsed or refractory CD20-positive follicular B-cell non-Hodgkin’s lymphoma. The firm plans to launch the product in Europe within the next few months, Schering said.

By staff writers
January 22, 2004

Related Reading

Schering starts testing optical mammo, September 12, 2003

Currency effects weigh down Schering results, August 8, 2003

Epix, Schering to partner on MRI contrast, May 27, 2003

Schering diagnostics business dips in 2002, February 28, 2003

Peregrine, Schering team up, January 7, 2003

Copyright © 2004

Page 1 of 593
Next Page